Cargando...

Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Guigao Lin, Kuo Zhang, Jinming Li
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2015-11-01
Series:International Journal of Molecular Sciences
Assuntos:
HBV
Acceso en liña:http://www.mdpi.com/1422-0067/16/11/25950
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!